169 related articles for article (PubMed ID: 37831226)
1. Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma.
Sun W; Liu K; Zhou H; Zhao F; Dong Y; Xu Y; Kong Y; Wang M; Cheng X; Chen Y
Med Oncol; 2023 Oct; 40(11):330. PubMed ID: 37831226
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Roles of
Wróblewska JP; Dias-Santagata D; Ustaszewski A; Wu CL; Fujimoto M; Selim MA; Biernat W; Ryś J; Marszalek A; Hoang MP
Cells; 2021 Aug; 10(9):. PubMed ID: 34571863
[TBL] [Abstract][Full Text] [Related]
3. Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
Iida Y; Salomon MP; Hata K; Tran K; Ohe S; Griffiths CF; Hsu SC; Nelson N; Hoon DSB
BMC Cancer; 2018 Oct; 18(1):1054. PubMed ID: 30373548
[TBL] [Abstract][Full Text] [Related]
4. Identification of recurrent mutational events in anorectal melanoma.
Yang HM; Hsiao SJ; Schaeffer DF; Lai C; Remotti HE; Horst D; Mansukhani MM; Horst BA
Mod Pathol; 2017 Feb; 30(2):286-296. PubMed ID: 27739435
[TBL] [Abstract][Full Text] [Related]
5.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
6. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
[TBL] [Abstract][Full Text] [Related]
7. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets.
Lyu J; Song Z; Chen J; Shepard MJ; Song H; Ren G; Li Z; Guo W; Zhuang Z; Shi Y
J Pathol; 2018 Mar; 244(3):358-366. PubMed ID: 29230811
[TBL] [Abstract][Full Text] [Related]
9. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
11. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
Newell F; Kong Y; Wilmott JS; Johansson PA; Ferguson PM; Cui C; Li Z; Kazakoff SH; Burke H; Dodds TJ; Patch AM; Nones K; Tembe V; Shang P; van der Weyden L; Wong K; Holmes O; Lo S; Leonard C; Wood S; Xu Q; Rawson RV; Mukhopadhyay P; Dummer R; Levesque MP; Jönsson G; Wang X; Yeh I; Wu H; Joseph N; Bastian BC; Long GV; Spillane AJ; Shannon KF; Thompson JF; Saw RPM; Adams DJ; Si L; Pearson JV; Hayward NK; Waddell N; Mann GJ; Guo J; Scolyer RA
Nat Commun; 2019 Jul; 10(1):3163. PubMed ID: 31320640
[TBL] [Abstract][Full Text] [Related]
12.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
13. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract][Full Text] [Related]
14. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
15. Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
Hou JY; Baptiste C; Hombalegowda RB; Tergas AI; Feldman R; Jones NL; Chatterjee-Paer S; Bus-Kwolfski A; Wright JD; Burke WM
Cancer; 2017 Apr; 123(8):1333-1344. PubMed ID: 28026870
[TBL] [Abstract][Full Text] [Related]
16. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic analysis of primary malignant melanoma of the esophagus reveals similar genetic patterns compared with epithelium-associated melanomas.
Li J; Liu B; Ye Q; Xiao X; Yan S; Guan W; He L; Wang C; Yu Z; Tai Z; Pei S; Ma Y; Li S; Wang Y; Wu N
Mod Pathol; 2022 Nov; 35(11):1596-1608. PubMed ID: 35688970
[TBL] [Abstract][Full Text] [Related]
18. Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature.
Chłopek M; Lasota J; Thompson LDR; Szczepaniak M; Kuźniacka A; Hińcza K; Kubicka K; Kaczorowski M; Newford M; Liu Y; Agaimy A; Biernat W; Durzyńska M; Dziuba I; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kato H; Kopczyński J; Michal M; Michal M; Pęksa R; Prochorec-Sobieszek M; Starzyńska A; Takahashi S; Wasąg B; Kowalik A; Miettinen M
Mod Pathol; 2022 Nov; 35(11):1609-1617. PubMed ID: 35978013
[TBL] [Abstract][Full Text] [Related]
19. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J
Br J Cancer; 2013 Aug; 109(3):559-64. PubMed ID: 23860532
[TBL] [Abstract][Full Text] [Related]
20. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI; Widmer DS; Narechania A; Eichhoff O; Freiberger SN; Wenzina J; Cheng PF; Mihic-Probst D; Desalle R; Dummer R; Levesque MP
Oncotarget; 2016 Nov; 7(47):77163-77174. PubMed ID: 27791198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
